Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation.

[1]  Christopher R. Ellis,et al.  Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE) , 2021, Circulation.

[2]  V. Reddy,et al.  Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device , 2021, Circulation.

[3]  P. Neužil,et al.  Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. , 2020, Journal of the American College of Cardiology.

[4]  P. Stella,et al.  Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. , 2020, The New England journal of medicine.

[5]  M. Price,et al.  The NCDR Left Atrial Appendage Occlusion Registry. , 2020, Journal of the American College of Cardiology.

[6]  S. Kische,et al.  Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage , 2019, Circulation. Arrhythmia and electrophysiology.

[7]  V. Reddy,et al.  EWOLUTION of Watchman Left Atrial Appendage Closure to Patients With Contraindication to Oral Anticoagulation. , 2019, Circulation. Arrhythmia and electrophysiology.

[8]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[9]  V. Reddy,et al.  Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes , 2018, Circulation.

[10]  Saibal Kar,et al.  5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. , 2017, Journal of the American College of Cardiology.

[11]  J. Messenger,et al.  Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries. , 2017, Journal of the American College of Cardiology.

[12]  W. O’Neill,et al.  Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. , 2017, Journal of the American College of Cardiology.

[13]  M. Price,et al.  Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. , 2017, Heart rhythm.

[14]  S. Kische,et al.  Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry , 2016, European heart journal.

[15]  Saibal Kar,et al.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.

[16]  M. Price,et al.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.

[17]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[18]  Frederick T. Han,et al.  Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. , 2013, Journal of the American College of Cardiology.

[19]  J. Messenger,et al.  The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.

[20]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[21]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[22]  S. Gallagher,et al.  Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism: NICE guidance , 2011, Heart.

[23]  S. Yakubov,et al.  Feasibility of closed-chest ligation of the left atrial appendage in humans. , 2011, Heart rhythm.

[24]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[25]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[26]  P. Teirstein,et al.  Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. , 2009, JACC. Cardiovascular interventions.

[27]  Stef van Buuren,et al.  Multiple imputation of discrete and continuous data by fully conditional specification , 2007 .

[28]  K. Chandrasekaran,et al.  Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation. , 2006, American heart journal.

[29]  J. Odell,et al.  Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.

[30]  N. Ammash,et al.  Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographics tudy , 1995 .